Vitamin D deficiency and mortality in patients receiving dialysis: The comprehensive dialysis study

Journal of Renal Nutrition

Volumn 23, Issue 6, 2013, Pages 422-427

  Anand, Shuchi ^a   Chertow, Glenn M ^a   Johansen, Kirsten L ^b,c   Grimes, Barbara ^c   Dalrymple, Lorien S ^d   Kaysen, George A ^d,e   Tamura, Manjula Kurella ^a,f  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; 25-HYDROXYVITAMIN D; DRUG DERIVATIVE; VITAMIN D;

AGED; ARTICLE; BLOOD; FEMALE; HOSPITALIZATION; HUMAN; MALE; MIDDLE AGED; MORTALITY; RENAL REPLACEMENT THERAPY; STATISTICS; UNITED STATES; VITAMIN D DEFICIENCY;

AGED; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; RENAL DIALYSIS; UNITED STATES; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84886299910     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2013.05.003     Document Type: Article

References (29)

1. Anand S., Kaysen G.A., Chertow G.M., et al. Vitamin D deficiency, self-reported physical activity and health-related quality of life: the Comprehensive Dialysis Study. Nephrol Dial Transplant 2011, 26:3683-3688.
2. Wolf M., Shah A., Gutierrez O., et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007, 72:1004-1013.
3. Bhan I., Burnett-Bowie S.A., Ye J., Tonelli M., Thadhani R. Clinical measures identify vitamin D deficiency in dialysis. Clin J Am Soc Nephrol 2010, 5:460-467.
4. Singer R.F. Vitamin D in dialysis: defining deficiency and rationale for supplementation. Semin Dial 2012, 26:40-46.
5. Jones G. Expanding role for vitamin D in chronic kidney disease: importance of blood 25-OH-D levels and extra-renal 1alpha-hydroxylase in the classical and nonclassical actions of 1alpha,25-dihydroxyvitamin D(3). Semin Dial 2007, 20:316-324.
6. Zehnder D., Bland R., Williams M.C., et al. Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab 2001, 86:888-894.
7. Hewison M., Zehnder D., Chakraverty R., Adams J.S. Vitamin D and barrier function: a novel role for extra-renal 1 alpha-hydroxylase. Mol Cell Endocrinol 2004, 215:31-38.
8. Melamed M.L., Thadhani R.I. Vitamin D therapy in chronic kidney disease and end stage renal disease. Clin J Am Soc Nephrol 2012, 7:358-365.
9. Drechsler C., Pilz S., Obermayer-Pietsch G., et al. Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients. Eur Heart J 2010, 31:2253-2261.
10. Drechsler C., Verduijn M., Pilz S., et al. Vitamin D status and clinical outcomes in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant 2011, 26:1024-1032.
11. London G.M., Guerin A.P., Verbeke F.H., et al. Mineral metabolism andarterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 2007, 18:613-620.
12. Matias P.J., Ferreira C., Jorge C., et al. 25-Hydroxyvitamin D3, arterial calcifications and cardiovascular risk markers in haemodialysis patients. Nephrol Dial Transplant 2009, 24:611-618.
13. Kutner N.G., Johansen K.L., Kaysen G.A., et al. The comprehensive dialysis study (CDS): a USRDS special study. Clin J Am Soc Nephrol 2009, 4:645-650.
14. Melamed M.L., Michos E.D., Post W., Astor B. 25-Hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008, 168:1629-1637.
15. Ginde A.A., Scragg R., Schwartz R.S., Camargo C.A. Prospective study of serum 25-hydroxyvitamin D level, cardiovascular disease mortality, and all-cause mortality in older U.S. adults. J Am Geriatr Soc 2009, 57:1595-1603.
16. Levin G.P., Robinson-Cohen C., de Boer I.H., et al. Genetic variants and associations of 25-hydroxyvitamin D concentrations with major clinical outcomes. JAMA 2012, 308:1898-1905.
17. Mehrotra R., Kermah D.A., Salusky I.B., et al. Chronic kidney disease, hypovitaminosis D, and mortality in the United States. Kidney Int 2009, 76:977-983.
18. Pilz S., Iodice S., Zitterman A., Grant W.B., Gandini S. Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. Am J Kidney Dis 2011, 58:374-382.
19. Wang A.Y., Lam C.W., Sanderson J.E., et al. Serum 25-hydroxyvitamin D status and cardiovascular outcomes in chronic peritoneal dialysis patients: a 3-y prospective cohort study. Am J Clin Nutr 2008, 87:1631-1638.
20. Gracia-Iguacel C., Gallar P., Qureshi A.R., et al. Vitamin D deficiency in dialysis patients: effect of dialysis modality and implications on outcome. J Ren Nutr 2010, 20:359-367.
21. Palmer S.C., McGregor D.O., Macaskill P., Craig J.C., Elder G.J., Strippoli G.F. Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med 2007, 147:840-853.
22. Chonchol M., Kendrick J., Targher G. Extra-skeletal effects of vitamin D deficiency in chronic kidney disease. Ann Med 2011, 43:273-282.
23. Liu P.T., Stenger S., Li H., et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006, 311:1770-1773.
24. Cuppari L., Garcia Lopes M.G., Kamimura M.A. Vitamin D biology: from the discovery to its significance in chronic kidney disease. J Ren Nutr 2011, 21:113-116.
25. Uhlig K., Eckardt K.U. A decade after the KDOQI CKD guidelines: impact on CKD guidelines. Am J Kidney Dis 2012, 60:705-706.
26. Autier P., Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med 2007, 167:1730-1737.
27. Armas L.A., Andukuri R., Barger-Lux J., Heaney R.P., Lund R. 25-Hydroxyvitamin D response to cholecalciferol supplementation in hemodialysis. Clin J Am Soc Nephrol 2012, 7:1428-1434.
28. Jean G., Terrat J.C., Vanel T., et al. Evidence for persistent vitamin D 1-alpha-hydroxylation in hemodialysis patients: evolution of serum 1,25-dihydroxycholecalciferol after 6 months of 25-hydroxycholecalciferol treatment. Nephron Clin Pract 2008, 110:c58-c65.
29. Stubbs J.R., Idiculla A., Slusser J., Menard R., Quarles L.D. Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD. J Am Soc Nephrol 2010, 21:353-361.